Bringing the fundamentals into focus…
Back to Acadia Pharmaceuticals Inc.
How Acadia Pharmaceuticals Inc. stacks up
ACAD · against 299 other Healthcare companies of similar size
Valuation
82/ 100
Near the top of its peers.
Ranked #56 of 300 · scores higher than 81% of peers
Bars: peers in each 10-point band of the valuation score34 peers with a valuation score of 80–89, including ACAD · Click a bar to see the companies
Why valuation scores 82?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its earnings yield and free cash flow yield, which are stronger than most Healthcare peers.
- EBITDA yield is close to the peer norm. EBITDA yield: 3.7% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 75% of peers. Free cash flow yield: 4.1% vs peer median 0.0%
- higher earnings for the price paid: stronger than 96% of peers. Earnings yield: 10.7% vs peer median 1.5%
Metric by metric
Position: dot = ACAD, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ACAD | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 296 reported | 10.8% | 2.4% | 96% | 30% | |
| EBITDA yieldHigher is better · 294 reported | 3.7% | 4.8% | 43% | 50% | |
| Free cash flow yieldHigher is better · 154 reported | 4.1% | 0.7% | 72% | 20% | |
| Book yieldHigher is better · 294 reported | 36.9% | 28.9% | 61% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ACADScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score